1.Application of Evidence-based Pharmacy in Anticoagulant Treatment Strategies during Continuous Renal Re-placement Therapy
Lian TANG ; Huijuan YAO ; Shuhong BU
China Pharmacy 2016;27(12):1648-1651
OBJECTIVE:To explore the role of clinical evidence-based pharmacy in anticoagulant treatment strategies during continuous renal replacement therapy (CRRT). METHODS:Taking a thrombocytopenia patient of anticoagulant treatment during CRRT for instance,clinical pharmacists analyzed the evidence of taken argatroban anticoagulant therapy during CRRT for high risk blooding and thrombocytopenia patients based on evidence-based pharmacy combined with clinical data,monitored the efficacy and safety and evaluated the treatment process. RESULTS:Totally five literature about anticoagulant treatment strategies during CRRT for high risk blooding and thrombocytopenia patients were obtained,including one systematic review,one RCT and three cohort studies. Based on the above evidences,good results were achieved in the clinical practice of this patient,no thrombotic or hemor-rhagic complications occurred in this patient,platelet count and coagulation indicators of patients also improved. CONCLUSIONS:Evidence-based pharmacy plays an important role in anticoagulant treatment strategies during CRRT.
2.Determination of lidocaine and its metabolites by HPLC to evaluate CYP3A activity of human liver microsomes
Shunguo ZHANG ; Yuenian TANG ; Shuhong BU
Chinese Pharmacological Bulletin 1987;0(03):-
AIMTo evaluate CYP3A activity of hum an liver microsomes by the ratio of lidocaine(LDC) to its metabolites. M ETHODSIn 1 g?L -1 microsomal protein lidocaine was incubated at 37 ℃ for 1 hour. Lidocaine, monoethylglycinexylidide(MEGX) and glycinexylidide(GX) were determined by HPLC. RESULTSThe linear regress equations fo r LDC, MEGX and GX were = 0 293 4 X- 0 005 661 (r= 0 9 99 7 )、= 0 791 3 X- 0 008 916 (r= 0 999 3 ) and = 0 679 9 X- 0 007 770 (r= 0 998 5 ). The best conditio n for the incubation test in vitro was 2 0 mg?L -1 LDC plus 1 0 g ?L -1 microsomal protein for 60 min. The mean (MEGX+GX)/LDC ratio was 3 2 8. CONCLUSIONThe (MEGX+GX)/LDC ratio can be used to evaluate C YP3A activity of human liver microsomes.
3.Cost- effectiveness Analysis of Four Therapeutic Schemes for Hp Infection in Children
Shunguo ZHANG ; Minling CHEN ; Yuenian TANG ; Shuhong BU ; Fang LI
China Pharmacy 2001;12(4):218-219
OBJECTIVE:To evaluate the economic effectiveness in different pharmacotherapeutic schemes for Hp infection in children.METHODS:To analyze four therapeutic schemes for Hp infection in children with cost - effectiveness analysis.RESULTS: The cost- effectiveness ratios of four therapeutic schemes were 14.92,8.85,8.37 and 8.58 respectively. CONCLUSIONS: scheme C(clarithromycin + bismuth potassium citrate + metronidazole)is the best one.
4.Cost - effectiveness Analysis of Four Therapeutic Schemes for Hp Infection in Children
Shunguo ZHANG ; Minling CHEN ; Yuenian TANG ; Shuhong BU ; Fang LI
China Pharmacy 1991;0(04):-
OBJECTIVE:To evaluate the economic effectiveness in different pharmacotherapeutic schemes for Hp infection in children.METHODS: To analyze four therapeutic schemes for Hp infection in children with cost - effectiveness analy-sis. RESULTS: The cost - effectiveness ratios of four therapeutic schemes were 14.92, 8.85, 8.37 and 8.58 respective-ly. CONCLUSIONS: scheme C(clarithromycin + bismuth potassium citrate + metronidazole)is the best one.
5.An Analysis of Use of the Antidiabetic Agents
Shunguo ZHANG ; Minling CHEN ; Yuenian TANG ; Shuhong BU ; Fang LI
Herald of Medicine 2001;(5):318-319
Objective:To find out the current situation of and objectively evaluate the use of the antidiabetic agents so as to provide reference information to the departments of production, sales and consumption of the agents. Methods:A analytic review of 6,639 020 prescriptions during the period of 1995~1999 was made regarding the costs and DDDs. Results: In recent 5 years, the annual increase rate of the expenses for was(36.03±11.92)%; and that of DDDs was 20.05%. The order of expenses for various antidiabetic agents from high to low was as follows: glicalazide, acarbose, glipizide and metformin, while that of DDDs was glicalazide, glipizide, metformin and acarbose. The percentage of expenditure for oral versus the injection antidiabetic agents was(87.08±3.50)% to(12.92±3.50)%. Conclusion: The antidiabetic agents is a kind of common drugs with a bright future of development.
6.Mechanism of Clinical Cross Allergy Reaction of β-lactam Antibiotics and Introduction of Related Treat-ment Processes in USA
Ping LI ; Shuhong BU ; Jia ZHOU ; Huijuan YAO ; Xinzhu LIU
China Pharmacy 2017;28(26):3711-3715
OBJECTIVE:To investigate the mechanism of cross allergy reaction during the application of β-lactam antibiotics, and to provide reference for rational drug use in clinic. METHODS:Based on study experience of author in UIC and its affiliated hospital during advanced study,according to the experience of drug use safety management in patients allergic to β-lactam antibiot-ics from Rush University Medical Center,the mechanism of cross allergy reaction during the application of β-lactam antibiotics was summarized,and the disposal procedure for patients allergic to β-lactam antibiotics in the Affiliated Hospital of UIC was intro-duced. RESULTS:The principal reason for cross allergy reaction induced by β-lactam antibiotics were same or similar side chains between drugs. Cross allergy reaction occurred when IgE recognized these side chains. The disposal procedure for patients allergic to β-lactam antibiotics in the Affiliated Hospital of UIC included that the indication of β-lactam use was evaluated;standard penicil-lin skin testing according to evaluation results,anti-infection treatment by Grade challenge β-lactam antibiotics and course and rap-id drug tolerance induction. CONCLUSIONS:The disposal method for patients allergic to β-lactam antibiotics in the Affiliated Hos-pital of UIC can provide new thought for domestic clinical pharmacists in rational drug use among the patiens with reported aller-gies to special group as pregnant women,children.
7.Preparation of Inclusion Complex of Diclofenac Sodium-?-Cyclodextrin Eyedrops
Zhiliang XU ; Songhua YAO ; Fang LI ; Yuenian TANG ; Shunguo ZHANG ; Shuhong BU
China Pharmacy 2001;0(12):-
OBJECTIVE:To establish the preparation process of inclusion complex of diclofenac sodium-?-cyclodextrin (DS-?-CD) eyedrops METHODS:The DS-?-CD was prepared by the stir method and identified with instrumental method The content of diclofenac sodium was detected by UV,HPLC RESULTS:The inclusion ratio of DS-?-CD was(67 48?2 96)% There was no difference between diclofenac sodium and DS-?-CD in UV absorption spectrum The crystal diffraction peak of DS inclosed in DS-?-CD disappeared in X-ray CONCLUSION:The DS-?-CD can be used as eyedrops in clinical practice
8.Quality Status Evaluation and Improvement Suggestions of Case Analysis Work of Clinical Pharmacists
Wei CAO ; Shuhong BU ; Jing XIA ; Qian WANG ; Tingting GUO ; Enjing ZHANG
China Pharmacist 2016;19(6):1129-1131
Objective: To provide reference for clinical pharmacists to write case analysis work .Methods: The reviews of 185 case analysis work of clinical pharmacists from the training bases all over the country were collected .Combined with the practical expe-rience of clinical teaching , the reviews were analyzed and discussed .Results:The problems in title , introduction , drug use analysis , summary and experience of the case analysis work were pointed out , and some improvement suggestions were provided , especially those for the improvement of case analysis evaluation form .Conclusion:Although the case analysis work has been screened by the teachers of training bases , the problems are still outstanding .The rationalization proposals provided in the paper maybe help improve the quality of case analysis work .
9.Pharmaceutical Care Practice for Admission Medication Reconciliation in the Internal Medicine Inpatient by Clinical Pharmacists
Huijuan YAO ; Ping LI ; Xinzhu LIU ; Shuhong BU ; Jian ZHANG
China Pharmacy 2017;28(32):4580-4584
OBJECTIVE:To explore the importance and necessity of clinical pharmacists in drug therapy for chronic disease patients,the feasibility of developing medication reconciliation (MR),and to provide reference for establishing the internal medicine working model of clinical pharmacy.METHODS:During May to Jul.2016,inpatients were selected from respiratory department of our hospital as subjects.After detailed pharmaceutical consultation,clinical pharmacist conducted MR for newly inpatients at the first day in the hospital.RESULTS:Through clinical pharmacists classified and organized the problems of drug use in the inpatients during medication,MR records of 98 inpatients were collected,involving 296 medical orders and 96 items of medication errors.Among MR patients,there were only 44 cases of good compliance (44.9%);some problems about drug use existed in other cases,including optional medication,improper usage and dosage,fearing of drug side effects and refusing to use drugs,drug withdrawal due to ADR,follow-up failure of special disease leading to excessive or inadequate dose,poor communication with doctors leading to medication errors,forgetting to take medication or missing,excessive medical treatment and so on.Most common medication error-inducing drugs type was cardiovascular drug,followed by respiratory drug and endocrine system drug.CONCLUSIONS:The development of MR by clinical pharmacists is helpful to identify and correct medication error,avoid potential medication error,and control disease.It can be used as a project of pharmaceutical care in department of internal medicine.